DE60331162D1 - Kombinationsprodukt bestehend aus einem inhibitor der src familie der nicht-rezeptor tyrosinkinasen und gemcitabin zur behandlung oder prophylaxe von pankreaskrebs - Google Patents

Kombinationsprodukt bestehend aus einem inhibitor der src familie der nicht-rezeptor tyrosinkinasen und gemcitabin zur behandlung oder prophylaxe von pankreaskrebs

Info

Publication number
DE60331162D1
DE60331162D1 DE60331162T DE60331162T DE60331162D1 DE 60331162 D1 DE60331162 D1 DE 60331162D1 DE 60331162 T DE60331162 T DE 60331162T DE 60331162 T DE60331162 T DE 60331162T DE 60331162 D1 DE60331162 D1 DE 60331162D1
Authority
DE
Germany
Prior art keywords
prophylaxis
inhibitor
treatment
tyrosinkinases
gemcitabin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60331162T
Other languages
German (de)
English (en)
Inventor
Alan Barge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of DE60331162D1 publication Critical patent/DE60331162D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Control And Other Processes For Unpacking Of Materials (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60331162T 2002-11-13 2003-11-07 Kombinationsprodukt bestehend aus einem inhibitor der src familie der nicht-rezeptor tyrosinkinasen und gemcitabin zur behandlung oder prophylaxe von pankreaskrebs Expired - Lifetime DE60331162D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0226434.9A GB0226434D0 (en) 2002-11-13 2002-11-13 Combination product
PCT/GB2003/004787 WO2004043472A1 (en) 2002-11-13 2003-11-07 Combination product of inhibitor of the src family of non-receptor tyrosine kinases and gemcitabine

Publications (1)

Publication Number Publication Date
DE60331162D1 true DE60331162D1 (de) 2010-03-18

Family

ID=9947715

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60331162T Expired - Lifetime DE60331162D1 (de) 2002-11-13 2003-11-07 Kombinationsprodukt bestehend aus einem inhibitor der src familie der nicht-rezeptor tyrosinkinasen und gemcitabin zur behandlung oder prophylaxe von pankreaskrebs

Country Status (16)

Country Link
US (1) US20060142297A1 (https=)
EP (1) EP1562612B1 (https=)
JP (1) JP2006508953A (https=)
KR (1) KR20050074573A (https=)
CN (1) CN100467027C (https=)
AT (1) ATE456370T1 (https=)
AU (1) AU2003279456B2 (https=)
BR (1) BR0316170A (https=)
CA (1) CA2504666A1 (https=)
DE (1) DE60331162D1 (https=)
ES (1) ES2338109T3 (https=)
GB (1) GB0226434D0 (https=)
NO (1) NO20052312L (https=)
NZ (1) NZ539514A (https=)
WO (1) WO2004043472A1 (https=)
ZA (1) ZA200503805B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9598601A (en) 2000-10-20 2002-04-29 Eisai Co Ltd Nitrogenous aromatic ring compounds
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
AU2003278383B2 (en) 2002-11-04 2007-06-14 Astrazeneca Ab Quinazoline derivatives as Src tyrosine kinase inhibitors
ATE508747T1 (de) 2003-03-10 2011-05-15 Eisai R&D Man Co Ltd C-kit kinase-hemmer
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
GB0412074D0 (en) 2004-05-29 2004-06-30 Astrazeneca Ab Combination product
ATE428421T1 (de) 2004-09-17 2009-05-15 Eisai R&D Man Co Ltd Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
GB0427697D0 (en) 2004-12-17 2005-01-19 Astrazeneca Ab Chemical process
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
CN104706637A (zh) 2006-05-18 2015-06-17 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
WO2008026748A1 (en) 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
JPWO2008088088A1 (ja) 2007-01-19 2010-05-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 膵癌治療用組成物
CA2676796C (en) 2007-01-29 2016-02-23 Eisai R & D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
MY162940A (en) 2009-08-19 2017-07-31 Eisai R&D Man Co Ltd Quinoline derivative-containing pharmaceutical composition
CN102958523B (zh) 2010-06-25 2014-11-19 卫材R&D管理有限公司 使用具有激酶抑制作用的组合的抗肿瘤剂
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
AR092289A1 (es) * 2011-11-14 2015-04-15 Sunshine Lake Pharma Co Ltd Derivados de aminoquinazolina y sus sales y metodos de uso
WO2013152313A1 (en) * 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
NZ714049A (en) 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
US20170022576A1 (en) 2015-03-18 2017-01-26 The Regents Of The University Of California Compositions and methods for identifying anti-cancer, anti-metastatic and anti-stress agents
MX373231B (es) 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd Agente anticancerigeno.
US12220398B2 (en) 2015-08-20 2025-02-11 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
ATE225655T1 (de) * 1998-09-25 2002-10-15 Warner Lambert Co Chemotherapie des krebses mit acetyldinalin in verbindung mit gemcitabin, capecitabin oder cisplatin
WO2001000213A1 (en) * 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
GB0101599D0 (en) * 2001-01-22 2001-03-07 Novartis Ag Organic compounds
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0412074D0 (en) * 2004-05-29 2004-06-30 Astrazeneca Ab Combination product

Also Published As

Publication number Publication date
CN1711094A (zh) 2005-12-21
NO20052312L (no) 2005-06-06
EP1562612A1 (en) 2005-08-17
CN100467027C (zh) 2009-03-11
KR20050074573A (ko) 2005-07-18
EP1562612B1 (en) 2010-01-27
ZA200503805B (en) 2006-09-27
AU2003279456B2 (en) 2007-05-17
BR0316170A (pt) 2005-09-27
GB0226434D0 (en) 2002-12-18
JP2006508953A (ja) 2006-03-16
NZ539514A (en) 2007-11-30
AU2003279456A1 (en) 2004-06-03
ATE456370T1 (de) 2010-02-15
ES2338109T3 (es) 2010-05-04
US20060142297A1 (en) 2006-06-29
CA2504666A1 (en) 2004-05-27
WO2004043472A1 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
DE60331162D1 (de) Kombinationsprodukt bestehend aus einem inhibitor der src familie der nicht-rezeptor tyrosinkinasen und gemcitabin zur behandlung oder prophylaxe von pankreaskrebs
CR20220537A (es) [1,3]DIAZINO[5,4-d]PIRIMIDINAS COMO INHIBIDORES DE HER2
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
MX2007006204A (es) Combinaciones que comprenden inhibidores de jak y cuando menos uno de entre inhibidores de bcr-abl, flt-3, fak o raf cinasa.
EA200501805A1 (ru) Фармацевтическая композиция, содержащая ингибитор фермента дипептидилпептидазы
TW200801008A (en) Protein kinase inhibitors
TW200604192A (en) Compounds and methods for inhibiting mitotic progression
ATE451369T1 (de) Piperidinopyrimidindipeptidylpeptidaseinhibitor n zur behandlung von diabetes
ZA200901037B (en) Pyrimidone compounds as GSK-3 inhibitors
IS2882B (is) Samsetning epóþílonhliðstæðna og virkra efna til efnameðferðar til þess að meðhöndla frumufjölgunarsjúkdóma
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
IL164187A0 (en) 7-Azaindole derivatives and pharmaceutical compositions containing the same
MY162563A (en) Compositions and methods for treating hyperproliferative diseases
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
DOP2011000074A (es) Compuestos y composiciones como inhibidores de proteina cinasa
NO20072558L (no) Mitotiske kineseinhibitorer og fremgangsmater for anvendelse derav
ATE322265T1 (de) Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
DK1545537T3 (da) Alfa-7-nikotinreceptoragonister og statiner i kombination
EA202193049A1 (ru) N-содержащее производное гетероарила и фармацевтическая композиция, содержащая его в качестве активного ингредиента для предупреждения или лечения рака
NO20060392L (no) Kombinasjon av SRC kinase inhibitorer kemoterapeutiske midler for behandling av proliferative sykdommer
TW200730190A (en) New combination to treat liver fibrosis
ATE457727T1 (de) Kombination aus pyrimidylaminobenzamid- verbindungen und imatinib zur behandlung oder verhinderung proliferativer erkrankungen
MX2023011759A (es) Composicion farmaceutica para prevenir o tratar la enfermedad renal cronica que incluye el derivado de glucagon.
WO2006128740A3 (en) Anti-vascular methods and therapies employing lysyl oxidase inhibitors
MX2022001702A (es) Inhibidores de jak.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition